Actinium Pharmaceuticals, Inc. (ATNM)

No Data available this quarter, please select a different quarter.

Negative EBIT growth while AGEN is at 99.97%. Joel Greenblatt would demand a turnaround plan focusing on core profitability.

Both companies face negative operating income growth. Martin Whitman would suspect broader market or cost hurdles.

Negative net income growth while AGEN stands at 93.80%. Joel Greenblatt would push for a reevaluation of cost or revenue strategies.

Negative EPS growth while AGEN is at 95.68%. Joel Greenblatt would expect urgent managerial action on costs or revenue drivers.

Negative diluted EPS growth while AGEN is at 95.68%. Joel Greenblatt would require immediate efforts to restrain share issuance or boost net income.

No Data available this quarter, please select a different quarter.

Both companies show negative OCF growth. Martin Whitman would analyze broader economic or industry conditions limiting cash flow.

Both companies show negative FCF growth. Martin Whitman would consider an industry-wide capital spending surge or margin compression.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

No Data available this quarter, please select a different quarter.

Both show negative 10Y OCF/share CAGR. Martin Whitman would question if the entire market or product set is shrinking or too capital-intensive.

Both show negative mid-term OCF/share growth. Martin Whitman might suspect a challenged environment or large capital demands for both.

Both face negative short-term OCF/share growth. Martin Whitman would suspect macro or cyclical issues hitting them both.

Negative 10Y net income/share CAGR while AGEN is at 94.11%. Joel Greenblatt sees a major red flag in long-term profit erosion.

Negative 5Y net income/share CAGR while AGEN is 83.34%. Joel Greenblatt would see fundamental missteps limiting profitability vs. the competitor.

Negative 3Y CAGR while AGEN is 55.33%. Joel Greenblatt might call for a short-term turnaround strategy or cost realignment.

Negative equity/share CAGR over 10 years while AGEN stands at 25.69%. Joel Greenblatt sees a fundamental red flag unless the competitor also struggles.

Negative 5Y equity/share growth while AGEN is at 1008.92%. Joel Greenblatt sees the competitor building net worth while this firm loses ground.

Negative 3Y equity/share growth while AGEN is at 3880.54%. Joel Greenblatt demands an urgent fix in capital structure or profitability vs. the competitor.

Asset growth well under 50% of AGEN's 210.91%. Michael Burry sees the competitor as far more aggressive in building resources or capacity.

We have a declining book value while AGEN shows 1096.60%. Joel Greenblatt sees a fundamental disadvantage in net worth creation vs. the competitor.

R&D growth drastically higher vs. AGEN's 38.01%. Michael Burry fears near-term margin erosion unless breakthroughs are imminent.

SG&A growth well above AGEN's 53.11%. Michael Burry sees potential margin erosion unless it translates into higher sales or brand equity.